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Effect of icodextrin on volume status, blood pressure and echo- Cardiovascular disease is the single most common
cardiographic parameters: A randomized study. Overhydration cause of death in dialysis patients. One of the known risk
is a risk factor for hypertension and left ventricular hypertrophy factors for cardiovascular mortality is left ventricularin peritoneal dialysis patients. Recently, a high prevalence of
hypertrophy (LVH) [1]. Although the pathophysiologysubclinical overhydration was observed in peritoneal dialysis
of LVH is undoubtedly multifactorially determined, over-patients. Aim of the present open-label randomized study was
to assess the effect of a icodextrin 7.5% solution on fluid status hydration is known to play a major role, at least in hemo-
[extracellular water (ECW) bromide dilution], blood pressure dialysis patients [2, 3]. Recently, we and others also showed
regulation (24-hour ambulatory measurements) and echocardio- a huge prevalence of subclinical overhydration in perito-graphic parameters during a study period of 4 months, and to
neal dialysis patients, despite the fact that patients wererelate the effect to peritoneal membrane characteristics (dialy-
adequately dialyzed according to Dialysis Outcome Qual-sate/plasma creatinine ratio). Forty peritoneal dialysis patients
(22 treated with icodextrin, 18 controls) were randomized to ity Initiative (DOQI) guidelines [4, 5]. Importantly, vol-
either treatment with icodextrin during the long dwell or stan- ume status was related to both hypertension and eccen-
dard glucose solutions. Thirty-two patients (19 treated with tric LVH [5].icodextrin, 13 controls] completed the study.
It has been suggested that the use of a glucose poly-The use of icodextrin resulted in a significant increase in daily
meric solution, icodextrin 7.5%, is able to improve vol-ultrafiltration volume (744  767 mL vs. 1670  1038 mL; P 
0.012) and a decrease in ECW (17.5  5.2 L vs. 15.8  3.8 L; ume status in peritoneal dialysis patients due to an im-
P  0.035). Also the change in ECW between controls and proved and prolonged ultrafiltration, especially during
patients treated with icodextrin was significant (1.7  3.3 L long dwells [6, 7]. Nevertheless, studies toward the effectvs. 0.9  2.2 L; P  0.013). The effect of icodextrin on ECW
of icodextrin on volume status in peritoneal dialysis pa-was not related to peritoneal membrane characteristics, but sig-
tients are scarce, whereas in the single published study,nificantly related to the fluid state of the patients (ECW:height)
(r  0.72; P  0.0001). Left ventricular mass (LVM) de- including patients on automated peritoneal dialysis, which
creased significantly in the icodextrin-treated group (241  53 assessed the effect of icodextrin on fluid state in more
grams vs. 228  42 grams; P  0.03), but not in the control detail, did not use a randomized design, did not applygroup.
reference techniques to assess volume status, and did notIn this randomized open-label study, the use of icodextrin
assess the effect of icodextrin on cardiac structure (8).resulted in a significant reduction in ECW and LVM. The effect
of icodextrin on ECW was not related to peritoneal membrane Moreover, it is not well known which patients would
characteristics, but was related to the initial fluid state of the benefit most of a potential beneficial effect of icodextrin.
patient.
From a theoretical point of view, especially patients with
a peritoneal membrane (so-called high transporters) [9]
would be expected to benefit, although in a recent studyKey words: peritoneal dialysis, fluid state, icodextrin, tracer dilution,
ambulatory blood pressure, echocardiography. of our group the effect of residual renal function on volume
status appeared to be more pronounced than the effect
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Table 1. Patient demographics
Group Icodextrin (N  22) Control (N  18)
Number
Male/female 14/8 15/3
CAPD/CCPD 16/6 15/3
MeanSD [range]
Age years 52.710.9 [35–69] 56.411.6 [36–71]
Weight kg 77.613.6 [46.1–98.1] 79.814.8 [54.1–109.1]
Body surface area m 2 1.90.2 [1.34–2.20] 2.00.2 [1.59–2.34]
Time on peritoneal dialysis months 19.115.8 [3–47] 25.118.0 [4–66]
Weekly Kt/V urea 2.50.6 [1.6–4.3] 2.40.7 [1.7–5.0]
Weekly creatinine clearance L/1.73 m2 85.640.0 [67.4–170.5] 67.233.4 [65.3–134.3]
Residal diuresis mL/24 hours 11311099 [0–4000] 1031849 [0–3490]
Residual glomerular filtration rate mL/min 5.43.6 [0–13.8] 4.13.2 [0–14.1]
D/P creatinine 0.640.11 [0.45–0.90] 0.650.09 [0.47–0.79]
Serum albumin g/L 31.63.5 [23.4–37.5] 31.82.8 [27.4–38.1]
Hemoglobin mmol/L 7.20.8 [5.5–8.7] 7.30.6 [6.4–8.6]
C-reactive protein mg/L 11.419.5 [2–89] 8.310.2 [2–37]
24-hour systolic blood pressure mm Hg 135.620.6 [100–177] 136.918.5 [105–177]
24-hour diastolic blood pressure mm Hg 81.211.9 [56–105] 84.210.6 [64–107]
Antihypertensive agents number 2.01.1 [0–4] 1.91.2 [0–4]
Patients on antihypertensive treatment % 90.9 89.9
Abbreviations are: CAPD, continuous ambulatory peritoneal dialysis; CCPD, continuous cyclic peritoneal dialysis. Data for patients whom were enrolled in the study.
fects of icodextrin in those patients with significant resid- Study design
ual function. In this open-label randomized multicenter study, un-
Aims of the present study were (1) to compare the selected peritoneal dialysis patients were randomized
effects of icodextrin on volume status, blood pressure, toward treatment with either the continuation of their
and cardiac structure in a randomized open-label design peritoneal dialysis prescription with standard glucose
using detailed methodology, and (2) to assess the effects
solutions, or treatment with icodextrin during nighttime
of icodextrin in relation to membrane permeability, re-
[in continuous ambulatory peritoneal dialysis (CAPD)sidual function, and volume status in an unselected group
patients] or daytime [in continuing cycling peritonealof peritoneal dialysis patients.
dialysis (CCPD) patients]. No other interventions in the
dialysate prescription were performed during the study
METHODS period. At the start of the study and after a follow-up
Patients period of 4 months, volume status, blood pressure, and
echocardiographic parameters were assessed.Forty stable peritoneal dialysis patients were included
Patients were recruited from five dialysis centers in the(29 males; 11 females). Patients with recent complications
southeastern part of The Netherlands and one dialysis(e.g., peritonitis, malignancy, or surgery), type I diabetes
mellitus, and congestive heart failure or coronary artery center in Germany. The study was approved by the Eth-
disease, defined as New York Heart Association (NYHA ics Committee of the University Hospital Maastricht. All
III and higher) were excluded. Patient characteristics are patients signed informed consent.
displayed in Table 1. Apart from the exclusion criteria,
no selection criteria were applied. Randomization procedure and power analysis
Patients with severe cardiac failure and/or coronary Patients were randomized with the use of sealed enve-
artery disease were excluded because the underlying dis- lopes. The primary outcome variable was the difference
ease might severely influence relations between fluid over- in extracellular water (ECW) between icodextrin-treated
load, blood pressure, and cardiac structure and, therefore,
patients and the control group. In order to detect a differ-obscure potentially important effects of icodextrin in
ence of 3 L ( 0.05, 1 0.20) between the icodextrin-a group of peritoneal dialysis patients without cardiac
and control groups, 33 patients would be needed. How-failure. Dry weight was assessed on clinical grounds ac-
ever, because we wished to include as many patientscording to the treating physician, with no signs of overhy-
as possible (maximum of 50) to maximize power, 50dration (i.e., an elevated central venous pressure or pe-
envelopes were available for randomization. As weripheral or pulmonary edema). The treatment goals for
learned that additional inclusion of patients in our regiontreatment adequacy were set according to the DOQI
was not possible, we terminated the study after the inclu-guidelines. Patients were treated with 1.36% glucose so-
lutions for the long dwell. sion of 40 patients.
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Study protocol scales was r  0.98 (P  0.0001). DEXA measurements
were performed in a standard fashion while the patientPatients were admitted to the research center at the
was lying in a supine position. From an x-ray source anddialysis department of the University Hospital of Maas-
K-edge filter below the patient, x-ray beams of stable-tricht in the early morning after an overnight fast. Perito-
energy radiation of 38 and 70 KeV were emitted. Theneal dialysis fluid was first drained before the measure-
composition of the soft tissue was estimated by the ratioments were started. After admission, tracer dilution
of beam attenuation at lower energy relative to themeasurements were performed and office blood pressure
higher energy in soft tissue pixels; this ratio is inverselywas measured. During this study period, patients were
and linearly related to the percentage fat [14]. Bodynot allowed to eat or drink. At noon, patients were al-
weight was computed by summation of body fat, leanlowed to eat a light meal, of which the total amount of
body mass, and bone cell mass. In patients randomizedfluid did not exceed 200 mL. Hereafter, echocardiogra-
as controls, the coefficient of variation of body weightphy was performed, followed by 24-hour ambulatory
assessed by DEXA between the beginning and end ofblood pressure measurements.
the study was 3.2%.Peritoneal dialysate and urine collections were per-
Fluid status. Patients received an orally administeredformed the day before the study. Patients randomized
dose of 30 mL (150 mmol/L) sodium bromide (NaBr)to icodextrin used this solution during the long dwell
(Pharmacologic Department, Academical Hospital Maas-(i.e, the nighttime dwell in CAPD patients and the day-
tricht, The Netherlands). Enrichments of NaBr in thetime dwell in CCPD patients).
body fluid were measured in serum. Immediately before
NaBr intake, a (background) blood sample was taken.Study parameters
After the equilibration time of 4 hours, a second bloodPeritoneal ultrafiltration. Peritoneal ultrafiltration was
sample was collected. The concentration of bromide inassessed with the use of the 24-hour dialysate collection,
serum was determined by gas chromatography [14]. Bro-performed before the start and the end of the study.
mide dilution spaces were calculated from the enrich-Peritoneal transport status. Within a maximum of 2
ment of bromide after 4 hours. The ECW was calculatedmonths before entry of the study the transport status
as the NaBr dilution space corrected for intracellularof the peritoneal membrane was characterized using a
space penetration of NaBr in erythrocytes, leukocytes,standard peritoneal equilibrium test after a 4-hour dwell
and secretory cells, for unequal NaBr concentrations inwith a 2.27% glucose-containing peritoneal dialysis solu-
the extracellular fluids (Gibbs-Donnan effect), and fortion. At entry of study, on the same day, a 24-hour
the concentration of water in the serum; therefore, NaBrcollection of the dialysis fluid and the urine was per-
dilution was multiplied by the following correction fac-formed to calculate the Kt/Vurea and the weekly creatinine
tor: 0.90 · 0.95 · 0.94  0.80 [15]. In patients randomizedclearance normalized to 1.73 m2 body surface area (BSA)
as controls, the coefficient of variation of ECW betweenand the residual glomerular filtration rate (rGFR). All
the beginning and end of the study was 12.6%.calculations were performed using peritoneal dialysis
Normalization of parameters. Regarding the relationAdequest software (Baxter Healthcare Corp., Deerfield,
between the effect of icodextrin with regard to the initialIL, USA) [11].
fluid state of the patient, extracellular volume was nor-Body weight and body composition. In order to obtain
malized both for BSA and height because the optimalmaximal accuracy, changes in body weight were assessed
normalization procedure for fluid status is not wellby dual-energy x-ray absorptiometry (DEXA) [12].
known in dialysis patients [16].DEXA (DPX-L; Lunar Radiation Corp., Madison, WI,
Echocardiography. Two-dimensional echocardiogra-USA) was used for measurement of fat mass, lean body
phy was performed using a HP Sonos 5500 ultrasoundmass (comprising muscle, inner organs, and body water),
system (Hewlett Packard, Palo Alto, CA, USA) with stan-and bone mineral density. Body weight was measured
dard imaging transducers with a frequency varying fromby DEXA because this method allows a very precise
1.6 to 3.2 MHz. Parameters included in the analysis weremeasurement of body weight, which is not influenced by
LVM and left ventricular end diastolic diameter (LVEDD)
clothing, which could disturb the assessment of discrete
as a parameter of left ventricular eccentric hypertrophy.
weight changes. Moreover, it allows a distinction be-
LVM was calculated according to the formula of Dev-
tween changes in lean body mass and fat mass (vide
ereux and Reichek [17]:
supra). It has been shown in dialysis patients that DEXA
measurements were linearly related to conventional gravi- LVM  1.04 [(LVEDD  IVST  PWT)3
metric weight procedures and were able to predict small
 (LVEDD)3] – 13.6
changes in body weight accurately [13]. In the present
study, the correlation coefficient between body weight where IVST is intraventricular septum thickness and
PWT is posterior wall thickness.measured by DEXA and by conventional gravimetric
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24-hour ambulatory blood pressure In all patients, 24- contrast to the control group, ECW declined significantly
in the group treated with icodextrin. In addition, thehour blood presssure measurements were performed us-
ing an oscillometric blood pressure monitor (Space-labs change in ECW between the icodextrin-treated and con-
trol group was significantly different (Fig. 1) (1.7 3.390207; Redmond, WA, USA). Blood pressure was mea-
sured every 15 minutes from 7 a.m till 11 p.m and every vs.0.9 2.2 L; P 0.013). Body weight and lean body
mass also decreased in the icodextrin-treated group, in30 minutes from 11 p.m. until 7 a.m. Measurements were
only included if more than 85% of the readings were contrast to control subjects (both P 0.03). The relation
between the change in body weight and lean body masssuccessful. If not, the measurement was repeated. For
the separation of day- and nighttime blood pressures, with changes in ECW did not reach significance.
The 24-hour blood pressure readings did not change“fixed” hours were 7 a.m. until 11 p.m for daytime and
11 p.m. until 7 a.m. for nighttime blood pressures [18]. significantly in the icodextrin-treated and control groups.
Nevertheless, LVM decreased in the icodextrin-treated
Statistics group, in contrast to the control group (Fig. 2). Still, no
direct relation between changes in ECW or body weightData are expressed as mean  SD. Differences be-
tween the icodextrin and control groups were assessed with changes in LVM was observed. Although the
change in LVEDD in the icodextrin-treated group waswith the unpaired Student t test. Changes within groups
were assessed with the paired Student t test. For data not significant, there was a significant relation between
the change in LVEDD and LVM (r  0.69; P  0.001).which were not normally distributed (ultrafiltration vol-
ume, rGFR, residual diuresis, total daily fluid removal,
Relation between fluid state, peritoneal membraneperitoneal glucose presecription, C-reactive protein), non-
characteristics, and the effect of icodextrinparametric tests were used (Mann-Whitney and Wilcoxon
tests, respectively). In icodextrin-treated patients, there was no relation
between peritoneal membrane characteristics and theCorrelations between variables were estimated by the
use of Pearson product moment correlations. P values decline in ECW, but a highly significant relation between
the initial fluid state of the patient, expressed as ECW:0.05 were considered significant.
BSA and the change in ECW was observed (r  0.75;
P  0.001) This relationship also remained significantRESULTS
when the initial fluid state was expressed as or as ECW:
Of the 40 patients that were included in the study, height (r  0.72; P  0.001) (Fig. 3).
22 patients were randomized to use icodextrin and 18
patients were randomized into the control group. Thirty- Effect of icodextrin on residual diuresis and rGFR
two patients (19 patients being treated with icodextrin Residual diuresis declined significantly in the icodex-
and 13 controls] completed the study. Three patients trin-treated group (Table 2) but also tended to decline
dropped out in the icodextrin group (one patient switched in the control group. GFR decreased slightly, but signifi-
to hemodialysis because of technique failure, one patient cantly, in the icodextrin-treated group but not in the
had a recovery of the renal failure and CAPD was stopped, control group.
and one patient developed a hypersensitivity reaction
during the use of icodextrin (exfoliative dermatitis) which
DISCUSSIONcompletely resolved after stopping the icodextrin. In the
The main results of this open-label randomized studycontrol group, five patients dropped out (two patients
are the significant effect of icodextrin on extracellularunderwent a renal transplantation during follow-up, two
volume, assessed by tracer dilution techniques, and thepatients developed peritonitis, and one patient was
significant relation between the initial fluid state of theswitched to hemodialysis because of technique failure).
patient and the effect of icodextrin on extracellularData for ECW and ambulatory blood pressure are
volume.available for all patients and for echocardiography in all
In contrast to the control group, extracellular volumebut one patient. Urine collections were missing in three
declined significantly in the group treated with icodex-patients being treated with icodextrin and two patients
trin, with a highly significant difference between the con-in the control group. Data presented in Table 2 comprise
trol and icodextrin-treated groups. The decline in extra-those who ended the study.
cellular volume is explained by the impressive effect
Effect of icodextrin on fluid state, body weight, of icodextrin on peritoneal ultrafiltration. The effect of
body composition, blood pressure, and icodextrin on ultrafiltration volume and extracellular vol-
echocardiographic parameters ume is in agreement with the study of Woodrow et al
[8] in patients on automated peritoneal dialysis. Never-Variables for ECW, 24-hour ambulatory blood pres-
sure, LVM and LVEDD are summarized in Table 2. In theless, this was a nonrandomized study using bioimped-
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Table 2. Data for patients who completed the study (mean  SE [range])
Beginning End P
Icodextrin-treated group (N  19)
ECW L 17.55.2 [9.0–29.0] 15.83.8 [8.3–23.9] 0.035
UF-volume mL 744767 [400–2500] 16701038 [200–4420] 0.012
Residual diuresis mL 11311099 [0–4000] 913962 [0–3800] 0.005
Daily fluid removal mL 1854908 [400–3800] 23811188 [340–4858] 0.031
Residual GFR mL/min 4.83.2 [0–9.0] 3.43.0 [0–9.3] 0.010
Systolic BP mm Hg 13821 [100–177] 13528 [100–194] NS
Diastolic BP mm Hg 8212 [56–105] 8011 [54–108] NS
LVM g 241.252.6 [125–346] 228.341.8 [120–307] 0.031
LVEDD mm 51.66.0 [38–62] 50.85.7 [37–60] NS
Glucose prescribed g/day 20099 [82–524] 16196 [61–490] 0.000
Body weight kg 76.613.8 [42.2–95.7] 74.914.5 [37.3–93.4] 0.002
Lean body mass kg 51.811.2 [29.5–69.5] 50.711.3 [27.7–70.0] 0.014
Fat mass kg 22.18.9 [9.9–42.5] 21.99.1 [8.2–42.8] NS
C-reactive protein mg/L 12.920.6 [2–89] 8.28.2 [2–30] NS
Hemoglobin mmol/L 7.20.7 [5.5–8.7] 7.51.0 [6.1–9.8] NS
Serum albumin g/L 32.13.3 [23.4–37.5] 31.94.6 [19.1–38.0] NS
Control group (N  13)
ECW L 16.53.6 [10.9–22.1] 17.44.7 [11.1–25.6] NS
UF-volume mL 907787 [820–2355] 1063960 [1320–2000] NS
Residual diuresis mL 1061890 [0–3490] 948858 [0–3100] NS
Daily fluid removal mL 1968980 [580–3790] 20011230 [370–4080] NS
Residual GFR mL/min 4.53.5 [0–14.1] 4.14.3 [0–16.4] NS
Systolic BP mm Hg 13821 [105–177] 13322 [94–177] NS
Diastolic BP mm Hg 8512 [64–107] 8011 [59–95] NS
LVM g 21942 [158–310] 22041 [170–320] NS
LVEDD mm 48.54.7 [42–56] 49.53.9 [43–57] NS
Glucose prescribed g/day 17458 [68–259] 17458 [68–259] NS
Body weight kg 79.611.7 [59.6–104.9] 80.013.1 [58.0–110.5] NS
Lean body mass kg 51.89.8 [34.4–63.8] 52.99.9 [36.8–71.4] NS
Fat mass kg 24.79.8 [8.7–40.5] 24.08.3 [7.9–35.5] NS
C-reactive protein mg/L 4.53.9 [2–15] 4.44.4 [2–16] NS
Hemoglobin mmol/L 7.10.6 [6.4–8.6] 7.30.5 [6.5–8.3] NS
Serum albumin g/L 32.13.3 [23.4–37.5] 31.63.8 [22.0–37.0] NS
Abbreviations are: ECW, extracellular water; UF-volume, peritoneal ultrafiltration volume; BP, blood pressure; GFR, glomerular filtration rate; LVM, left
ventricular mass; LVEDD, left ventricular end-diastolic diameter; Glucose prescribed, daily peritoneal glucose prescription; Daily fluid removal, sum of peritoneal
fluid removal and diuresis.
ance measurements as a marker of volume state. In the likely that the decline in body weight and lean body mass
also reflects an improvement in fluid state. The fact thatpresent study, we chose to use tracer dilution techniques
in the assessment of volume state, as the reliability of the relation between the change in body weight and
ECW did not reach significance might be due to variationvolume measurements by bioimpedance appears to be
especially compromised in overhydrated patients [19, 20]. in ECW measurements. Another explanation for this
phenomenon might reside in the fact that, even duringIn contrast to Woodrow et al [8], we did not observed
a significant effect on 24-hour ambulatory blood pressure a relatively short time period, changes in body composi-
tion, unrelated to fluid state, may occur in peritonealmeasurements. It is possible that absence of a significant
effect of icodextrin on blood pressure regulation might dialysis patients [22]. In a recent analysis, we observed
significant changes in body cell mass and fat mass inbe explained (1) by the fact that, in line with a recent
survey of patients on peritoneal dialysis [21], most of individual patients during a 4-month follow-up period
(submitted data).our patients used antihypertensive medication, which
may have blunted the effect of changes in volume status, Moreover, the fact that in the icodextrin-treated group,
ECW, body weight, lean body mass, and LVM all changedand (2) that other factors than fluid state, such as arterial
wall properties, have an important on blood pressure in significantly in the same direction appears to be a strong
argument for a beneficial effect of icodextrin on fluidperitoneal dialysis patients [5]. In contrast, in the icodex-
trin group, LVM decreased significantly, in contrast to state in unselected peritoneal dialysis patients.
Body fat mass did not decrease in the icodextrin-controls.
In addition to the decline in ECW and the reduction treated group, despite the reduction in peritoneal glucose
prescription. This might be explained by the fact thatin LVM, also body weight and lean body mass declined
significantly in the icodextrin-treated patients, whereas the follow-up time was relatively short or by the fact
that the reduction in glucose prescription ( 40 grams/body weight remained stable in the control group. It is
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Fig. 3. Relation between the initial fluid state and the change in extra-Fig. 1. Change in extracellular water in the icodextrin-treated and
cellular water after treatment with icodextrin. r  0.72; P  0.001.control groups. Difference between icodextrin and control groups at
P 0.013. Box indicates 25th and 75th percentiles (thick line is median
value) and capped bars indicate minimum and maximum value (exclud-
ing outliers)
nounced in patients with an expanded ECW compart-
ment). The mechanisms behind this phenomenon cannot
be elucidated from the present study. One could specu-
late that the effect of icodextrin on peritoneal ultrafiltra-
tion is most pronounced in overhydrated patients (e.g.,
due to a higher peritoneal capillary pressure). Another
hypothetical explanation could reside in the possibility
that the increased peritoneal ultrafiltration by icodextrin
would result in increased thirst and water intake in nor-
movolemic patients, counteracting the effect on volume
status.
The fact that icodextrin was most effective in patients
with an expanded ECW leads to the problem of the
diagnosis of overhydration in peritoneal dialysis patients.
Although this problem is beyond the scope of the present
study, it should be mentioned that clinical examination
appears to be insufficiently sensitive for this purpose, as
a high prevalence of subclinical overhydration, assessed
by tracer dilution methods, was observed in an unse-
lected group of peritoneal dialysis patients with adequate
treatment according to DOQI guidelines with dry weight
Fig. 2. Change in left ventricular mass in the icodextrin-treated and
prescription according to the clinical judgment of thecontrol groups. Difference between icodextrin and control groups at
P 0.050. Box indicates 25th and 75th percentiles (thick line is median physician [4, 5]. Nevertheless, we admit that the use of
value) and capped bars indicate minimum and maximum value (exclud- tracer dilution techniques is not suitable for daily clinical
ing outliers)
practice. As already mentioned, multifrequency-bioimpe-
dance analysis (MF-BIA), which is a simple and noninva-
sive tool, carries the disadvantage of a lack of agreement
with tracer dilution techniques, especially in overhydratedday) was too small to achieve a significant reduction in
patients [17, 20]. In a recent study by our group in perito-body fat.
neal dialysis patients, it was not possible to find a cut-The effect of icodextrin on ECW was not related to
off point for MF-BIA that could predict left ventricularperitoneal membrane characteristics but highly signifi-
cantly related to volume status (i.e., much more pro- dilatation with adequate sensitivity and specificity [17].
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Additional studies, including an adequate sample of con- and LVM during a 4-month period compared to a control
group using standard glucose solutions. The effect oftrol subjects, should be carried out in order to find
whether it is possible to elucidate a cut-off point for MF- icodextrin was not found to be related to peritoneal
membrane characteristics, but was related to the initialBIA measurements which also carries a predictive value
for hemodynamic abnormalities in peritoneal dialysis pa- fluid state of the patient.
tients.
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